Information for patients, carers and families

VPRIV (velaglucerase alfa) is indicated for long-term enzyme replacement therapy in patients with type 1 Gaucher disease.

This site is designed as a resource to provide information about velaglucerase alfa.

The information on this website is intended only to provide information about velaglucerase alfa. This information should not be used in place of advice from your GP or other healthcare professional.

This website is intended for residents of the United Kingdom only. This website has been produced by Shire HGT, a business within the Shire group of companies. The website has been developed in accordance with industry and legal standards to provide information for the general public, patients and their families, and also healthcare professionals about velaglucerase alfa. Shire Human Genetic Therapies makes every reasonable effort to include accurate and current information. However, the information provided on the website is not exhaustive. References for published sources of information cited on this website have been provided on the relevant pages.

Sponsored by Shire HGT, a business within the Shire group of companies.

Registered in Jersey 99854.
Registered Office: 22 Grenville Street, St Helier, Jersey JE4 8PX.
UK Offices: Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP.

Email: medinfoglobal@shire.com